Bausch Health Companies Inc (VRX):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Bausch Health Companies Inc (VRX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7221
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:119
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bausch Health Companies Inc(Bausch Health) formerly known as Valeant Pharmaceuticals International Inc, develops, manufactures and markets several branded, over-the-counter (OTC) and generic drugs. The company also offers medical devices such as medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Bausch Health offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada, Mexico, the US and countries in Europe, North Africa, Asia and South America. Bausch Health is headquartered in Laval, Quebec, Canada.

Bausch Health Companies Inc (VRX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Bausch Health Companies Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Bausch Health Companies Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 9
Bausch Health Companies Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Bausch Health Companies Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 11
Bausch Health Companies Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
Bausch Health Companies Inc, Medical Equipment, Deal Details 15
Asset Purchase 15
Valeant Pharma to Acquire Rights to IBSchek in US and Canada form Commonwealth Labs 15
Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 16
Valeant Pharma to Acquire Dental Whitening Business from Klox Technologies 17
Private Equity 18
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 18
Partnerships 19
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 19
Namtall Enters into Licensing Agreement with Valeant Pharma 21
Bausch & Lomb Enters Into Licensing Agreement With Cirle 22
Unilens Vision Sciences Amends Licensing Agreement With Bausch & Lomb 23
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 24
Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 25
Valeant Pharmaceuticals International Partners With Living Proof 26
Obagi Medical Products Extends Distribution Agreement With Suneva Medical 27
Bausch & Lomb Enters Into Distribution Agreement With PhysIOL For Hydrophilic Acrylic Intraocular Lenses 28
Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 29
Obagi Medical Products Enters Into Distribution Agreement With Suneva Medical For ReGenica Facial Rejuvenation Complex 30
Solta Medical Expands Co-Marketing Agreement With SkinCeuticals 31
Bausch & Lomb Enters Into Agreement With Cirle For Medical Technologies 32
Sinclair IS Pharma Enters Into Distribution Agreement With Valeant Pharma For Injectable Dermal Fillers 33
Solta Medical Enters Into Co-Marketing Agreement With SkinCeuticals 34
OrthoScan Enters Into Distribution Agreement With Ziehm Imaging 35
Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 36
Equity Offering 37
Valeant Pharma Plans to Raise Funds through Public Offering of Securities 37
Bausch & Lomb Withdraws IPO 38
Solta Medical Completes Public Offering Of Common Stock For US$17 Million 39
Debt Offering 40
Valeant Pharma Raises USD586.5 Private Placement of 8.5% Notes Due 2027 40
Valeant Pharma Raises USD1.17 Billion in Private Placement of 9.25% Senior Notes Due 2026 41
Valeant Pharma Raises USD1.18 Billion in Private Placement of 9% Notes Due 2025 42
Valeant Pharma Raises USD591.4 Million in Private Placement of 5.5% Notes Due 2025 43
Valeant Pharma Raises USD801.4 Million in Private Placement of Notes 44
Valeant Pharma Raises USD1.5 Billion in Public Offering of 7% Notes Due 2024 45
Valeant Pharma Raises USD1 Billion in Public Offering of 6.5% Notes Due 2022 46
Solta Medical Completes Private Placement Of Debt Securities For US$40 Million 47
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 48
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 49
Asset Transactions 50
Valeant Pharma International May Sell Eye Surgery Assets to Carl Zeiss Meditec 50
Valeant Pharma May Sell its Eye-Surgery Equipment Business for up to USD2.5 Billion 51
Almirall Plans to Acquire Dermatology Assets from Valeant Pharmaceuticals 52
Stryker Acquires Neuro Portfolio Assets of Synergetics 53
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 54
Acquisition 55
Valeant Pharma Sells Sprout Pharma 55
Pershing Square Capital Management Sells its Investment in Valeant Pharma 56
Bausch & Lomb Acquires Doctor’s Allergy Formula 57
Valeant Pharma Acquires Synergetics 58
Valeant Pharma to Acquire Unilens Vision 60
Valeant Canada Acquires CROMA Pharma Canada 61
Valeant Pharma Completes Acquisition Of Solta Medical For US$250 Million 62
Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 64
Synergetics USA Acquires M.I.S.S. Ophthalmics For US$3 Million 66
OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 67
Valeant Pharma Acquires Croma-Pharma Polska And Croma Romania From Croma-Pharma 68
Solta Medical Completes Acquisition Of Sound Surgical For Up To US$40 Million 69
Bausch & Lomb Completes Acquisition Of Remaining Stake In Technolas Perfect Vision From 20/10 Perfect Vision For US$631 Million 70
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 72
Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 74
Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 75
Bausch Health Companies Inc – Key Competitors 76
Bausch Health Companies Inc – Key Employees 77
Bausch Health Companies Inc – Locations And Subsidiaries 78
Head Office 78
Other Locations & Subsidiaries 78
Recent Developments 87
Financial Announcements 87
May 08, 2018: Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance 87
Feb 28, 2018: Valeant Announces Fourth-Quarter And Full-Year 2017 Financial Results 90
Nov 07, 2017: Valeant Announces Third-Quarter 2017 Results 94
Aug 08, 2017: Valeant Announces Second-Quarter 2017 Results 96
May 09, 2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range 99
Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance 100
Corporate Communications 104
Sep 15, 2017: Valeant Commits $200,000 to Support Hurricane Relief Efforts 104
Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International 105
Jun 19, 2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications 106
Jun 19, 2017: John Paulson Joins Valeant Board Of Directors 107
May 05, 2017: Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership 108
Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 109
Legal and Regulatory 110
Sep 28, 2018: Salix Resolves Legacy SEC Investigation With No Penalty 110
May 15, 2018: Kyros Law Announces that it is Filing Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors 111
May 08, 2018: Valeant Will Become Bausch Health Companies 112
Apr 12, 2018: Cosmo Pharmaceuticals announces unfavourable award of Arbitral Tribunal in respect of request to terminate Uceris License Agreement with Valeant 113
Product News 114
Apr 27, 2018: Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting 114
May 22, 2017: Bausch + Lomb Introduces renu Advanced Formula Multi-Purpose Solution 116
Other Significant Developments 117
Sep 27, 2018: Bausch Health Releases First Annual Corporate Social Responsibility Report 117
Nov 15, 2017: Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program 118
Appendix 119
Methodology 119
About GlobalData 119
Contact Us 119
Disclaimer 119

List of Tables
Bausch Health Companies Inc, Medical Equipment, Key Facts, 2017 2
Bausch Health Companies Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Bausch Health Companies Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Bausch Health Companies Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 9
Bausch Health Companies Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Bausch Health Companies Inc, Deals By Market, 2012 to YTD 2018 11
Bausch Health Companies Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
Valeant Pharma to Acquire Rights to IBSchek in US and Canada form Commonwealth Labs 15
Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 16
Valeant Pharma to Acquire Dental Whitening Business from Klox Technologies 17
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 18
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 19
Namtall Enters into Licensing Agreement with Valeant Pharma 21
Bausch & Lomb Enters Into Licensing Agreement With Cirle 22
Unilens Vision Sciences Amends Licensing Agreement With Bausch & Lomb 23
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 24
Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 25
Valeant Pharmaceuticals International Partners With Living Proof 26
Obagi Medical Products Extends Distribution Agreement With Suneva Medical 27
Bausch & Lomb Enters Into Distribution Agreement With PhysIOL For Hydrophilic Acrylic Intraocular Lenses 28
Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 29
Obagi Medical Products Enters Into Distribution Agreement With Suneva Medical For ReGenica Facial Rejuvenation Complex 30
Solta Medical Expands Co-Marketing Agreement With SkinCeuticals 31
Bausch & Lomb Enters Into Agreement With Cirle For Medical Technologies 32
Sinclair IS Pharma Enters Into Distribution Agreement With Valeant Pharma For Injectable Dermal Fillers 33
Solta Medical Enters Into Co-Marketing Agreement With SkinCeuticals 34
OrthoScan Enters Into Distribution Agreement With Ziehm Imaging 35
Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 36
Valeant Pharma Plans to Raise Funds through Public Offering of Securities 37
Bausch & Lomb Withdraws IPO 38
Solta Medical Completes Public Offering Of Common Stock For US$17 Million 39
Valeant Pharma Raises USD586.5 Private Placement of 8.5% Notes Due 2027 40
Valeant Pharma Raises USD1.17 Billion in Private Placement of 9.25% Senior Notes Due 2026 41
Valeant Pharma Raises USD1.18 Billion in Private Placement of 9% Notes Due 2025 42
Valeant Pharma Raises USD591.4 Million in Private Placement of 5.5% Notes Due 2025 43
Valeant Pharma Raises USD801.4 Million in Private Placement of Notes 44
Valeant Pharma Raises USD1.5 Billion in Public Offering of 7% Notes Due 2024 45
Valeant Pharma Raises USD1 Billion in Public Offering of 6.5% Notes Due 2022 46
Solta Medical Completes Private Placement Of Debt Securities For US$40 Million 47
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 48
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 49
Valeant Pharma International May Sell Eye Surgery Assets to Carl Zeiss Meditec 50
Valeant Pharma May Sell its Eye-Surgery Equipment Business for up to USD2.5 Billion 51
Almirall Plans to Acquire Dermatology Assets from Valeant Pharmaceuticals 52
Stryker Acquires Neuro Portfolio Assets of Synergetics 53
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 54
Valeant Pharma Sells Sprout Pharma 55
Pershing Square Capital Management Sells its Investment in Valeant Pharma 56
Bausch & Lomb Acquires Doctor’s Allergy Formula 57
Valeant Pharma Acquires Synergetics 58
Valeant Pharma to Acquire Unilens Vision 60
Valeant Canada Acquires CROMA Pharma Canada 61
Valeant Pharma Completes Acquisition Of Solta Medical For US$250 Million 62
Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 64
Synergetics USA Acquires M.I.S.S. Ophthalmics For US$3 Million 66
OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 67
Valeant Pharma Acquires Croma-Pharma Polska And Croma Romania From Croma-Pharma 68
Solta Medical Completes Acquisition Of Sound Surgical For Up To US$40 Million 69
Bausch & Lomb Completes Acquisition Of Remaining Stake In Technolas Perfect Vision From 20/10 Perfect Vision For US$631 Million 70
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 72
Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 74
Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 75
Bausch Health Companies Inc, Key Competitors 76
Bausch Health Companies Inc, Key Employees 77
Bausch Health Companies Inc, Other Locations 78
Bausch Health Companies Inc, Subsidiaries 78

List of Figures
Bausch Health Companies Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Bausch Health Companies Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Bausch Health Companies Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Bausch Health Companies Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Bausch Health Companies Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Bausch Health Companies Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 9
Bausch Health Companies Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Bausch Health Companies Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 11

★海外企業調査レポート[Bausch Health Companies Inc (VRX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HCA Healthcare Inc (HCA):企業の財務・戦略的SWOT分析
    HCA Healthcare Inc (HCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Community Health Systems Inc (CYH):企業の財務・戦略的SWOT分析
    Community Health Systems Inc (CYH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Safe Orthopaedics SA (SAFOR):企業の財務・戦略的SWOT分析
    Summary Safe Orthopaedics SA (Safe Orthopaedics) is medical device company that manufactures and markets devices for spinal surgery. The company’s products comprise implants and surgical instruments. It also offers modular cervical cages, percutaneous auto-correction screws, modular anchorage screws …
  • Singapore Airlines Ltd:企業のM&A・事業提携・投資動向
    Singapore Airlines Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Singapore Airlines Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Emirates NBD Bank:企業の戦略・SWOT・財務分析
    Emirates NBD Bank - Strategy, SWOT and Corporate Finance Report Summary Emirates NBD Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Shell Pakistan Ltd (SHEL):企業の財務・戦略的SWOT分析
    Summary Shell Pakistan Ltd (Shell Pakistan), a subsidiary of Royal Dutch Shell plc is an oil and gas company that markets petroleum products and compressed natural gas. The company operates through three segments such as retail, lubricants and aviation. It retail segment offers a range of fuels such …
  • Pakistan International Airlines Corporation:企業の戦略・SWOT・財務分析
    Pakistan International Airlines Corporation - Strategy, SWOT and Corporate Finance Report Summary Pakistan International Airlines Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • SAS Institute Inc.:戦略・SWOT・企業財務分析
    SAS Institute Inc. - Strategy, SWOT and Corporate Finance Report Summary SAS Institute Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Bengal Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Bengal Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Bengal Energy Ltd (Bengal Energy), formerly Avery Resources Inc is an oil and gas exploration and production company that acquires, explores, and produces prospective light oil-weighted onshore assets …
  • Vaxart Inc-製薬・医療分野:企業M&A・提携分析
    Summary Vaxart Inc (Vaxart) focuses on the development of recombinant vaccines based on its proprietary oral vaccine delivery platform. The company is currently developing tablet vaccines for seasonal and pandemic influenza, norovirus, and Respiratory Syncytial Virus (RSV). Vaxart’s vaccine delivery …
  • Novelis Inc
    Novelis Inc - Strategy, SWOT and Corporate Finance Report Summary Novelis Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Crown Resorts Ltd:戦略・SWOT・企業財務分析
    Crown Resorts Ltd - Strategy, SWOT and Corporate Finance Report Summary Crown Resorts Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Zincore Metals Inc:企業の戦略・SWOT・財務分析
    Zincore Metals Inc - Strategy, SWOT and Corporate Finance Report Summary Zincore Metals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Axis Bank Ltd (AXISBANK):企業の財務・戦略的SWOT分析
    Axis Bank Ltd (AXISBANK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • ValiRx Plc (VAL)-医療機器分野:企業M&A・提携分析
    Summary ValiRx Plc (ValiRx) is a biopharmaceutical company that develops technologies and therapeutic options for the treatment of cancer. The company’s products and technology include GeneICE-silencing rebellious genes, GeneICE – BCL-2, VAL201-prostate cancer, NAV3 cancer screening test and VAL401- …
  • Zeta Petroleum Plc (ZTA):企業の財務・戦略的SWOT分析
    Summary Zeta Petroleum Plc (Zeta) is an oil and gas exploration and production company. The company explores, develops and produces natural gas and crude oil. It owns and operates oil and gas assets such as Bobocu Gas Field, Suceava Concession, Jimbolia Oil Field, and Grivita Nord Oil Field. Zeta’s …
  • Aggreko Plc (AGK):企業の財務・戦略的SWOT分析
    Aggreko Plc (AGK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Vectrus Inc (VEC):企業の財務・戦略的SWOT分析
    Vectrus Inc (VEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Rio Tinto:戦略・SWOT・企業財務分析
    Rio Tinto - Strategy, SWOT and Corporate Finance Report Summary Rio Tinto - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • pSivida Corp (PSDV)-製薬・医療分野:企業M&A・提携分析
    Summary pSivida Corp (pSivida) is a specialty pharmaceutical company that offers development of miniaturized, sustained-release drug delivery products and technologies. The company’s products include iluvien, retisert and durasert. Its durasert is an injectable, miniaturized, sustained-release drug …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆